But David Christensen, director of congressional affairs for the Family Research Council, said Dr. Crawford acted properly in taking time to consider the legal and regulatory issues that go along with this type of dual marketing approval. The implications go beyond Plan B and beyond just scientific considerations, he said. “This wasn't politics,” he said. “This was just prudence.”
If the FDA had relied on its normal process for evaluating Plan B, it would already have been approved. DR. WOOD